Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923726 · ClinicalTrials.gov registry record · NA
Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 2,692
- Enrollment target
NCT02923726: Completed NA study, sponsored by Boston Scientific Corporation.
NCT02923726 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 2,692 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02923726, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,692 participants
- Enrollment target
Study Summary
The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for implantable cardioverter-defibrillator (ICD) therapy and programmed according to current guidance of higher rate cut-offs and therapy delays. The time to first all-cause shock will be tested in subjects with standard therapy (ATP and shocks) compared to subjects programmed to shock only to assess equivalency.
Primary Outcome
The incidence of all-cause shocks in subjects programmed with shocks only will be compared with subjects programmed to standard therapy (ATP and shock) to assess equivalency. All shocks delivered by the device were adjudicated by an external committee as to whether they were appropriately or inappropriately delivered. All shocks, appropriate and inappropriate, contributed to the evaluation of this endpoint.
Interventions
- DEVICE Arm 1 (ATP+Shock)
- DEVICE Arm 2 (shock only)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,692 participants |
| Start Date | 2016-09-30 |
| Est. Completion | 2023-07-06 |
| Phase | NA |
What the finished NCT02923726 record still lists
NCT02923726 is an interventional study that assigns participants to a tested intervention. Its 2,692 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% higher).
The record links to 0 conditions, and to 2 interventions - of which Arm 1 (ATP+Shock) is the first listed.
NCT02923726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02923726 about?
NCT02923726 is a clinical study titled "Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP". The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for implantable cardioverter-defibrillator (ICD) therapy and programmed according to current guidance of higher rate cut-offs and therapy delays. The time to first all-cause shock...
What is the current status of trial NCT02923726?
This trial is currently completed. It is a NA study. The enrollment target is 2,692 participants. The study started on 2016-09-30. Estimated completion is 2023-07-06.
What interventions are being tested in trial NCT02923726?
The interventions under investigation include: Arm 1 (ATP+Shock) (DEVICE), Arm 2 (shock only) (DEVICE).
Who is sponsoring clinical trial NCT02923726?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02923726's enrollment target sits among peer trials
2,692 44th of 2000 higher than 1,957 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05111925 · 2,690 participants
Pre- and Post-neuromusculoskeletal Injury Risk Evaluation for Return-to-Duty Enhancement
- NCT04073420 · 2,700 participants
Medtronic Cardiac Surgery PMCF Registry
- NCT05125939 · 2,700 participants
Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
- NCT05586776 · 2,700 participants · Phase 4
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI